Survey Shows Gaps In CoA Monitoring; FDA Sees Guidance, Tracking As Fixes
This article was originally published in The Gray Sheet
Executive Summary
FDA says it is monitoring newly implemented measures aimed at bolstering design, execution and completion of Condition of Approval (CoA) studies
You may also be interested in...
No More Secrets: CDRH Post-Approval Study Web Site Goes Live April 6
A public Web site tracking device companies' progress on FDA-required post-approval studies is scheduled to go live April 6
No More Secrets: CDRH Post-Approval Study Web Site Goes Live April 6
A public Web site tracking device companies' progress on FDA-required post-approval studies is scheduled to go live April 6
FDA Proposes Status Reports, Web Postings For Postmarket Studies
Device firms should submit interim status reports on mandated post-approval studies to FDA every six months for a study's first two years and annually thereafter, a newly released draft guidance states